Becton Dickinson and Co (BDX) Stock Analysis

Verdict: WATCH (do not buy)

Pure-play MedTech focus and pharmacy robotics drive margin re-rating, but trading above analyst targets with 0 insider buys urges patience.

Investment score: 55/100

Analysis as of

Is Becton Dickinson and Co stock worth reviewing? The TradeMates thesis

TradeMates scores BDX at 55/100 (WATCH). While strategic repositioning and pharmacy robotics expansion improve long-term margins, current valuation above consensus analyst targets limits 90-day upside.

7-factor investment score

Becton Dickinson and Co opportunities and risks

What speaks for BDX

What speaks against BDX

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
BDX59.7x2.6x15.7x46.1%4.5%4.8%
ABT38.0x3.7x21.1x57.1%9.7%4.9%
ISRG52.7x13.4x35.5x67.2%25.5%2.3%
SYK31.4x4.5x19.3x65.2%14.4%4.0%
BSX18.5x3.2x13.5x71.2%17.5%5.5%
EW51.2x7.9x31.1x78.0%15.4%2.8%
Peer median38.0x4.5x21.1x67.2%15.4%4.0%

Frequently asked questions about Becton Dickinson and Co (BDX)

Is BDX stock a good investment?

The TradeMates model rates Becton Dickinson and Co as WATCH (do not buy) with an investment score of 55/100. TradeMates scores BDX at 55/100 (WATCH). While strategic repositioning and pharmacy robotics expansion improve long-term margins, current valuation above consensus analyst targets limits 90-day upside. This is algorithmic model output, not personal investment advice.

Is BDX stock a buy?

The TradeMates model verdict for BDX is WATCH (do not buy) with an investment score of 55/100. Treat this as a model signal to review, not a personal buy recommendation.